Ursodeoxycholic Acid Market, By Dosage Form (Solid Dosage Form and Liquid Dosage Form), By Mode of Extraction (Synthetic and Biological), By Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Others), By Distribution Channel (Hospi

Ursodeoxycholic Acid Market, By Dosage Form (Solid Dosage Form and Liquid Dosage Form), By Mode of Extraction (Synthetic and Biological), By Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Ursodeoxycholic acid is a bile acid produced by the liver that helps in digestion and absorption of consumed fats. It is prescribed for treating various liver related conditions such as primary biliary cirrhosis (PBC) and gallstones. Global ursodeoxycholic acid market growth is driven by rising prevalence of liver diseases and increasing awareness about benefits of ursodeoxycholic acid in their treatment. The market players are investing heavily in R&D to develop new formulations and delivery forms of ursodeoxycholic acid to expand consumer base.

Market Dynamics:

Global ursodeoxycholic acid market growth is driven by rising geriatric population prone to developing liver disorders, increasing healthcare expenditure in developing nations, and growing adoption of ursodeoxycholic acid as first line therapy for PBC. However, high treatment costs and availability of alternative treatment options can hamper the market growth. Development of ursodeoxycholic acid formulations targeted towards specific indications and emergence of novel technologies for enhancing its bioavailability present high growth opportunities for market players. Stringent regulations for drug approvals can hamper the market growth.

Key features of the study:

This report provides in-depth analysis of the global ursodeoxycholic acid market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global ursodeoxycholic acid market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, and Lannett Company

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global ursodeoxycholic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ursodeoxycholic acid market

Detailed Segmentation-

Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)

Solid Dosage Form

Liquid Dosage Form

Mode of Extraction Insights (Revenue, USD Mn, 2019 - 2031)

Synthetic

Biological

Application Insights (Revenue, USD Mn, 2019 - 2031)

Gastrointestinal Disorders

Liver Disorders

Cystic Fibrosis

Others

Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)

Hospitals and Clinics

Retail Pharmacies

Online Pharmacies

Regional Insights (Revenue, USD Mn 2019 - 2031)

North America

U.S.

Canada

Latin America

Brazil

Argentina

Mexico

Rest of Latin America

Europe

Germany

U.K.

Spain

France

Italy

Russia

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

GCC Countries

Israel

Rest of Middle East

Africa

South Africa

North Africa

Central Africa

Key Players Insights

Dipharma Francis Srl

ERREGIERRE S.p.A.

Grindeks

Industria Chimica Emiliana

Mitsubishi Tanabe Pharma Corporation

Zhongshan Belling Biotechnology Co.

Glenmark Pharmaceutical Limited

Abil Chempharma Private Limited

Biotavia Labs Pvt Ltd

Daewoong Bio Inc.

PharmaZell GmbH

Suzhou Tianlu Bio-pharmaceutical Co., Ltd.

Falk Pharma

Teva Pharmaceuticals

Epic Pharma

Lannett Company, Inc.

Mylan N.V.

Bruschettini S.p.A.

Impax Laboratories, Inc.

Shanghai Pharma